Sirtex profits up eightfold
Friday, 28 August, 2009
Medical device company, Sirtex, best known for its anti-cancer SIR-Spheres, has announced an impressive boost in revenues of 72 per cent over the past financial year.
In an ASX announcement, the company has indicated a 42 per cent increase in sales of its flagship product, leading to a net profit before tax of $23 million, up from $2.5 million the previous financial year.
SIR-Spheres experienced growth in all markets, up 28 per cent in the US, 117 per cent in Europe and 17 per cent in Asia Pacific.
In today's trading, Sirtex (ASX:SRX) was up 7.7% to $4.64.
CTA granted for CAR-T cell therapy for multiple myeloma
The Therapeutic Goods Administration has granted Clinical Trial Approval for KMCAR T-cell...
2026 Snow Fellowship recipients to receive $24m in biomedical funding
Australian biomedical researchers Dr Deborah Burnett, A/Prof Sudarshini Ramanathan and Dr Ira...
$780m Sydney Biomedical Accelerator gains its founding Executive Director
Professor Victoria Cogger has been appointed as founding Executive Director of the Sydney...
